MedTrace Logo

A 48 Week Study to Evaluate the Efficacy and Safety of Two (2) EYS606 Treatment Regimens in Subjects With Active Chronic Non-infectious Uveitis (CNIU)

NCT04207983 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2022-03-10

No results posted yet for this study

Summary

The objective of the study is to evaluate the efficacy and safety of two different treatment regimens of EYS606.

Conditions

  • Non-infectious Uveitis

Interventions

COMBINATION_PRODUCT

EYS606

EYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle

Sponsors & Collaborators

  • Eyevensys

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-03
Primary Completion
2021-10-05
Completion
2021-10-05
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04207983 on ClinicalTrials.gov